A Research Center Devoted to Fight Castleman Disease
The Center for Study & Treatment of Castleman & Inflammatory Lymphadenopathies (CSTL) was started by CDCN Co-Founder Dr. Fagjenbaum at the Perelman School of Medicine at the University of Pennsylvania. It is the first Center integrating top-notch clinical care, clinical trial opportunities, and basic, translational, and clinical research for CD in the country. The vision of the CSTL is a future where every patient diagnosed with any form of Castleman disease has an effective treatment so that Castleman disease does not limit their life.
The Center includes leading patient care provided by Drs. Adam Cohen and Sunita Nasta. The Center has launched a clinical trial of a new treatment for idiopathic multicentric Castleman disease called sirolimus. Patients have the opportunity to contribute samples to cutting-edge research through Castlebank and data from medical records to the ACCELERATE Registry. Dr. Fajgenbaum is proud to lead the Center as both a physician- scientist and patient to advance treatments and cures for Castleman disease.
Learn more about the CSTL at UPenn here.